Key result
Cancer-related hypercoagulability stems from disturbed endogenous heparin balance and specific patient, tumor, and treatment factors.
Why the study?
Although the link between cancer and thrombosis has long been known, the mechanisms underlying this correlation are not fully characterized.
Population
Cancer patients
Design
Review
Authors
Loading...
Highlights therapy-specific thrombotic risks for cancer care decisions; extends mechanistic framework but leaves open prospective validation.
This review outlines the mechanisms of cancer-related hypercoagulability, categorizing them into Type I and Type II etiologies, including the thrombogenic risk of various cancer therapies.
Nasser et al. (2020) conducted a review in Cancer-related hypercoagulability. Mechanisms of cancer-related hypercoagulability include disturbed endogenous heparin balance (Type I) and patient, tumor, or treatment-related factors such as specific cancer medications (Type II).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: